Marco Hernández-Enríquez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marco Hernández-Enríquez has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Manel Sabaté
Interventional Cardiology Department, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain (M.S.).
9 shared publications - Salvatore Brugaletta
University of Barcelona
9 shared publications - Nicolas Boudou
Clinique Saint Augustin Bordeaux France
4 shared publications Xavier Freixa
Cardiology Department, Cardiovascular Institute, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
4 shared publications- Didier Carrié
Department of Cardiology, Toulouse University Hospital, Toulouse, France
3 shared publications - Francisco Campelo-Parada
Hôpital Rangueil CHU
3 shared publications
Latest Publications
- 23 January 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (2) , 411-412
Reply to “what have we learnt from the use of Papyrus covered stent in France and Spain?”
- 23 January 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (2) , 411-412
Reply to “what have we learnt from the use of Papyrus covered stent in France and Spain?”
- 21 October 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (5) , 874-881
Use and outcomes of the PK Papyrus covered stent in France: SOS PK Papyrus Registry
Objectives: To evaluate the rate of procedural success and long‐term outcomes of the PK Papyrus (PKP) covered stent (CS).Background: CS are essential in the treatment of coronary artery perforation (CAP). They have also been used to treat coronary artery aneurysms. Limited evidence is available on clinical outcomes with the PKP.Methods: This was a multicenter, observational, retrospective, and prospective study. Consecutive patients undergoing intentional PKP implantation in 22 centers in France were included. The primary endpoint was the rate of procedural success. Secondary endpoints included rates of death, myocardial infarction (MI), target lesion revascularization (TLR), in‐stent restenosis (ISR), and stent thrombosis (ST).Results: Data from 130 patients were analyzed (mean age 72.5 ± 10.5 years; 71% men). The main indication for PKP was CAP, in 84 patients (65%). Delivery success was achieved in 95% and procedural success in 91%. During the in‐hospital stay, 15 patients died (12%) and 7 (5%) presented with ST. Data from 127 patients were available at 19.2 ± 12.8 month follow‐up. Thirty‐three patients died (26%), 15 (12%) had an MI and 21 (17%) presented with TLR. TLR was due to ISR in 12 patients (9%), 10 had definite ST (8%) and 1 patient for stent under‐expansion.Conclusions: The principal indication for PKP was CAP. PKP had high rates of delivery and procedural success. At long‐term follow‐up, there was a high rate of TLR, mainly due to ISR and ST. These results are consistent with previously reported data in these clinical settings.
- 21 October 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (5) , 874-881
Use and outcomes of the PK Papyrus covered stent in France: SOS PK Papyrus Registry
Objectives: To evaluate the rate of procedural success and long‐term outcomes of the PK Papyrus (PKP) covered stent (CS).Background: CS are essential in the treatment of coronary artery perforation (CAP). They have also been used to treat coronary artery aneurysms. Limited evidence is available on clinical outcomes with the PKP.Methods: This was a multicenter, observational, retrospective, and prospective study. Consecutive patients undergoing intentional PKP implantation in 22 centers in France were included. The primary endpoint was the rate of procedural success. Secondary endpoints included rates of death, myocardial infarction (MI), target lesion revascularization (TLR), in‐stent restenosis (ISR), and stent thrombosis (ST).Results: Data from 130 patients were analyzed (mean age 72.5 ± 10.5 years; 71% men). The main indication for PKP was CAP, in 84 patients (65%). Delivery success was achieved in 95% and procedural success in 91%. During the in‐hospital stay, 15 patients died (12%) and 7 (5%) presented with ST. Data from 127 patients were available at 19.2 ± 12.8 month follow‐up. Thirty‐three patients died (26%), 15 (12%) had an MI and 21 (17%) presented with TLR. TLR was due to ISR in 12 patients (9%), 10 had definite ST (8%) and 1 patient for stent under‐expansion.Conclusions: The principal indication for PKP was CAP. PKP had high rates of delivery and procedural success. At long‐term follow‐up, there was a high rate of TLR, mainly due to ISR and ST. These results are consistent with previously reported data in these clinical settings.
- 1 April 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 123 (7) , 1120-1126
Comparison of the Frequency of Thrombocytopenia After Transfemoral Transcatheter Aortic Valve Implantation Between Balloon-Expandable and Self-Expanding Valves
- 1 April 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 123 (7) , 1120-1126
Comparison of the Frequency of Thrombocytopenia After Transfemoral Transcatheter Aortic Valve Implantation Between Balloon-Expandable and Self-Expanding Valves
- 23 September 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (7) , 1344-1351
Thrombocytopenia after transcatheter aortic valve implantation. A comparison between balloon‐expandable and self‐expanding valves
Background: Thrombocytopenia after transcatheter aortic valve implantation (TAVI) is common and has been related to higher mortality and major complications. No comparison between balloon‐expandable (BEV) and self‐expanding valves (SEV) regarding drop platelet count (DPC) has been reported to date. The objectives of this study were to analyze the differences in DPC between BEVs or SEVs and their prognostic implications in clinical outcomes.Methods: We retrospectively analyzed patients undergoing TAVI. Platelet counts after TAVI were collected. Two groups were created: DPC ≤ 30% and DPC > 30%. VARC‐2 criteria were used to define outcomes.Results: Study population was composed of 195 patients (age 77.5 ± 6.7, 57.4% males). All of them but one experienced DPC (mean DPC 31.9 ± 15.3%). DPC was significantly higher among the patients treated with BEV compared to those treated with SEV (36.3 ± 15.1% vs 27.7 ± 14.4, P < 0.001). After multivariate analysis, the use of BEV was independently associated with a higher rate of DPC > 30% (67.4% vs 36.0%; OR 3.4; 95% CI, 1.42‐8.16). At 30 days, the DPC > 30% was associated with a higher rate of life‐threatening/major bleeding, major vascular complications, in‐hospital sepsis and mortality. At one year, there were no statistically significant differences in the mortality rate between groups (6.35% vs 10.0%, HR 1.54; 95% CI, 0.56–4.25).Conclusions: In this study, the use of BEV was associated with a higher risk of DPC after TAVI. A DPC rate > 30% was associated with an increased risk of major complications at 30 days.
- 23 September 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (7) , 1344-1351
Thrombocytopenia after transcatheter aortic valve implantation. A comparison between balloon‐expandable and self‐expanding valves
Background: Thrombocytopenia after transcatheter aortic valve implantation (TAVI) is common and has been related to higher mortality and major complications. No comparison between balloon‐expandable (BEV) and self‐expanding valves (SEV) regarding drop platelet count (DPC) has been reported to date. The objectives of this study were to analyze the differences in DPC between BEVs or SEVs and their prognostic implications in clinical outcomes.Methods: We retrospectively analyzed patients undergoing TAVI. Platelet counts after TAVI were collected. Two groups were created: DPC ≤ 30% and DPC > 30%. VARC‐2 criteria were used to define outcomes.Results: Study population was composed of 195 patients (age 77.5 ± 6.7, 57.4% males). All of them but one experienced DPC (mean DPC 31.9 ± 15.3%). DPC was significantly higher among the patients treated with BEV compared to those treated with SEV (36.3 ± 15.1% vs 27.7 ± 14.4, P < 0.001). After multivariate analysis, the use of BEV was independently associated with a higher rate of DPC > 30% (67.4% vs 36.0%; OR 3.4; 95% CI, 1.42‐8.16). At 30 days, the DPC > 30% was associated with a higher rate of life‐threatening/major bleeding, major vascular complications, in‐hospital sepsis and mortality. At one year, there were no statistically significant differences in the mortality rate between groups (6.35% vs 10.0%, HR 1.54; 95% CI, 0.56–4.25).Conclusions: In this study, the use of BEV was associated with a higher risk of DPC after TAVI. A DPC rate > 30% was associated with an increased risk of major complications at 30 days.
- 28 May 2018
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 31 (5) , 617-623
Outcomes after use of covered stents to treat coronary artery perforations. Comparison of old and new‐generation covered stents
Objectives: To compare outcomes in patients receiving polytetrafluoroethylene (PTFE) and polyurethane (PL) covered stents (CS) after coronary artery perforation (CAP).Background: The prognosis of CAP has improved with the advent of CSs. Information is scarce about the outcomes of new‐generation CSs.Methods: Sixty‐one patients were treated with CSs in a 5‐years period (age = 77 ± 8.75% males). Procedural and clinical data were retrospectively collected. The primary endpoint was procedural success. Secondary endpoints included death and major adverse cardiac events (MACE) defined as a composite of death, myocardial infarction, target vessel, and lesion revascularization and need for surgical repair).Results: Twenty‐two (36%) received PL‐CSs and 39 (65%) PTFE‐CSs. There were no differences in procedural success (86% vs 69%, P = 0.216). Time to deliver was shorter with PL‐CS despite larger length of stents (8[11] vs 15[16] min, P = 0.001; 20[5] vs 16[3] mm, P < 0.001). This group had lower rate of pericardial effusion and cardiac arrest (41% vs 72%, P = 0.028; 5% vs 26%, P = 0.045). At 1‐year follow‐up, MACE rates were similar (58% vs 56%, P = 1.000) with atrend toward TVR in the PL‐CS arm (21% vs 5%, P = 0.083). No differences were found in mortality (26% vs 41%, P = 0.385). Each group had 1 stent thrombosis and in‐stent restenosis trended higher in the PL‐CS group (12% vs 3%, P = 0.223).Conclusions: Time to deliver was shorter with the PL‐CS and resulted in lower rate of pericardial effusion and cardiac arrest. However, there were no significant differences in procedural success and 1‐year follow‐up MACE in patients treated with PL‐CS or PTFE‐CS.
- 28 May 2018
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 31 (5) , 617-623
Outcomes after use of covered stents to treat coronary artery perforations. Comparison of old and new‐generation covered stents
Objectives: To compare outcomes in patients receiving polytetrafluoroethylene (PTFE) and polyurethane (PL) covered stents (CS) after coronary artery perforation (CAP).Background: The prognosis of CAP has improved with the advent of CSs. Information is scarce about the outcomes of new‐generation CSs.Methods: Sixty‐one patients were treated with CSs in a 5‐years period (age = 77 ± 8.75% males). Procedural and clinical data were retrospectively collected. The primary endpoint was procedural success. Secondary endpoints included death and major adverse cardiac events (MACE) defined as a composite of death, myocardial infarction, target vessel, and lesion revascularization and need for surgical repair).Results: Twenty‐two (36%) received PL‐CSs and 39 (65%) PTFE‐CSs. There were no differences in procedural success (86% vs 69%, P = 0.216). Time to deliver was shorter with PL‐CS despite larger length of stents (8[11] vs 15[16] min, P = 0.001; 20[5] vs 16[3] mm, P < 0.001). This group had lower rate of pericardial effusion and cardiac arrest (41% vs 72%, P = 0.028; 5% vs 26%, P = 0.045). At 1‐year follow‐up, MACE rates were similar (58% vs 56%, P = 1.000) with atrend toward TVR in the PL‐CS arm (21% vs 5%, P = 0.083). No differences were found in mortality (26% vs 41%, P = 0.385). Each group had 1 stent thrombosis and in‐stent restenosis trended higher in the PL‐CS group (12% vs 3%, P = 0.223).Conclusions: Time to deliver was shorter with the PL‐CS and resulted in lower rate of pericardial effusion and cardiac arrest. However, there were no significant differences in procedural success and 1‐year follow‐up MACE in patients treated with PL‐CS or PTFE‐CS.
- Open Access
- 25 January 2018
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 31 (4) , 465-470
Long‐term outcomes of rotational atherectomy of underexpanded stents. A single center experience
Objectives: To analyze the procedural and long‐term outcomes of the use of rotational atherectomy (RA) in underexpanded stents in our cohort and to provide an overview of currently available data on this technique.Background: Stent underexpansion (SU) has been related to stent thrombosis and restenosis. RA has been used to treat undilatable SU as a bail‐out strategy with encouraging results.Methods: This is an observational, single‐center study. We included patients who underwent stentablation between 2013 and 2017. Baseline demographics, procedural results, in‐hospital major adverse cardiac events (MACE), and long‐term follow‐up MACE were retrospectively collected.Results: A total of 11 patients (90.9% males, mean age 65.4 ± 18.6) were included in this study. Median left ventricle ejection fraction was 53.5% [46.2‐55]. Median calculated Syntax score was 16 [9‐31] and 45.5% of patients were admitted for acute coronary syndrome. Radial approach was used in 63.6% of cases. Most patients only required one burr (45% used a 1.5 mm diameter burr) during the intervention. Procedural success was achieved in 90.9% of the cases. Acute lumen gain was 42.7% [30.7‐61.49]. There were no in‐hospital deaths or MACE. At a median follow‐up of 26 months, only one patient (9.1%) suffered MACE in the context of acute coronary syndrome, and two patients (18.2%) required non‐target lesion revascularization. No deaths were reported.Conclusions: RA of under expanded stents is a feasible option with a high rate of procedural success. At long‐term follow‐up, all of them were alive and 90.9% of patients remained free from MACE.
- 25 January 2018
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 31 (4) , 465-470
Open AccessLong‐term outcomes of rotational atherectomy of underexpanded stents. A single center experience
Objectives: To analyze the procedural and long‐term outcomes of the use of rotational atherectomy (RA) in underexpanded stents in our cohort and to provide an overview of currently available data on this technique.Background: Stent underexpansion (SU) has been related to stent thrombosis and restenosis. RA has been used to treat undilatable SU as a bail‐out strategy with encouraging results.Methods: This is an observational, single‐center study. We included patients who underwent stentablation between 2013 and 2017. Baseline demographics, procedural results, in‐hospital major adverse cardiac events (MACE), and long‐term follow‐up MACE were retrospectively collected.Results: A total of 11 patients (90.9% males, mean age 65.4 ± 18.6) were included in this study. Median left ventricle ejection fraction was 53.5% [46.2‐55]. Median calculated Syntax score was 16 [9‐31] and 45.5% of patients were admitted for acute coronary syndrome. Radial approach was used in 63.6% of cases. Most patients only required one burr (45% used a 1.5 mm diameter burr) during the intervention. Procedural success was achieved in 90.9% of the cases. Acute lumen gain was 42.7% [30.7‐61.49]. There were no in‐hospital deaths or MACE. At a median follow‐up of 26 months, only one patient (9.1%) suffered MACE in the context of acute coronary syndrome, and two patients (18.2%) required non‐target lesion revascularization. No deaths were reported.Conclusions: RA of under expanded stents is a feasible option with a high rate of procedural success. At long‐term follow‐up, all of them were alive and 90.9% of patients remained free from MACE.
- 1 December 2017
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 13 (11) , 1365-1366
Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve. Moving to the percutaneous approach
- 1 December 2017
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 13 (11) , 1365-1366
Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve. Moving to the percutaneous approach
- 21 March 2017
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 72 (3) , 349-350
Emergency percutaneous embolization of iatrogenic right coronary artery-pleural space communication
(2017). Emergency percutaneous embolization of iatrogenic right coronary artery-pleural space communication. Acta Cardiologica: Vol. 72, No. 3, pp. 349-350.
- 21 March 2017
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 72 (3) , 349-350
Emergency percutaneous embolization of iatrogenic right coronary artery-pleural space communication
(2017). Emergency percutaneous embolization of iatrogenic right coronary artery-pleural space communication. Acta Cardiologica: Vol. 72, No. 3, pp. 349-350.
- 15 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 229, 19-20
Successful percutaneous coronary intervention of total chronic occlusion of the left main coronary artery: A feasible option?
- 15 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 229, 19-20
Successful percutaneous coronary intervention of total chronic occlusion of the left main coronary artery: A feasible option?
- 1 September 2016
- Published by Elsevier in Resuscitation
- Vol. 106, 108-112
Safety of glycoprotein IIb/IIIa inhibitors in patients under therapeutic hypothermia admitted for an acute coronary syndrome
- 1 September 2016
- Published by Elsevier in Resuscitation
- Vol. 106, 108-112
Safety of glycoprotein IIb/IIIa inhibitors in patients under therapeutic hypothermia admitted for an acute coronary syndrome